Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 99

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 99
---
SE on November 4, 2024, Enfusion announced its
financial results for the third quarter of 2024 and provided financial guidance for the full year 2024 based on then-current market conditions and expectations. Enfusion announced that it expected GAAP revenues for the full year 2024 to be between
$202 million and $205 million, which had been updated from Enfusion’s previous guidance of between $200 million and $210 million.

Over the course of the weeks of November 4 and November 11, 2024, representatives of Enfusion management and Goldman Sachs held
a number of follow-up meetings with potential counterparties.

On November 6, 2024,
Enfusion entered into a confidentiality agreement with Party Q, a financial sponsor firm.

Also on November 6, 2024, at the
direction of the Special Committee, representatives of Goldman Sachs distributed a bid process letter to each of Clearwater, Party A, Party B, Party C, Party D, the Party E Consortium, Party F, Party I, Party K, Party L, Party M, Party N, Party O,
Party P and Party Q, which requested first-round proposals by November 19, 2024. The process letter instructed bidders to specify the amount of consideration they would pay and to assume a fixed total dollar value to terminate the TRA,
derived from the TRA Guidance (to be provided to the prospective bidders prior to the bid date) and any independent calculations by the

64

prospective bidder, and to confirm in writing that, in the event and to the extent the acceleration of payments associated with the TRA were waived in full or in part, the full waived value would
accrue to the benefit of Enfusion Stockholders on a dollar-for-dollar basis. The process letter also requested that bidders indicate whether they were pre-conditioning their bids and a potential transaction irrevocably on approval by the Special Committee and a majority of the unaffiliated Enfusion Stockholders.

On November 7, 2024, Enfusion entered into a confidentiality agreement with Party R, a financial sponsor firm. At the direction of
the Special Committee, representatives of Goldman Sachs distributed a bid process letter to Party R.

On November 8, 2024, the
Special Committee held a meeting with representatives of Dechert and Goldman Sachs in attendance. Representatives of Goldman Sachs briefed the Special Committee on the status of the strategic transaction process, including the engagement with
bidders